The US market has shown robust performance of late, up 2.0% in the past week and up a significant 32% in the past year, while earnings are expected to grow 15% annually over the next few years . In this vibrant environment, identifying high-growth technology stocks means looking for companies with strong innovation potential and adaptability to maintain momentum alongside these promising market trends.
|
Name |
Sales growth |
Profit growth |
Growth assessment |
|---|---|---|---|
|
Super microcomputer |
23.83% |
24.32% |
★★★★★★ |
|
Ardelyx |
25.24% |
69.64% |
★★★★★★ |
|
Sarepta therapies |
24.00% |
42.91% |
★★★★★★ |
|
Clene |
78.50% |
60.16% |
★★★★★★ |
|
TG Therapeutics |
34.66% |
56.98% |
★★★★★★ |
|
Alkami technology |
21.89% |
98.60% |
★★★★★★ |
|
Alnylam pharmaceutical products |
22.45% |
70.66% |
★★★★★★ |
|
Travere Therapeutics |
31.70% |
72.51% |
★★★★★★ |
|
Seen |
22.57% |
71.80% |
★★★★★★ |
|
ImmunoGen |
26.00% |
45.85% |
★★★★★★ |
Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.
Let’s take a look at some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the development and commercialization of novel therapies for rare diseases, with a market capitalization of $2.47 billion.
Operations: Soleno Therapeutics is committed to developing therapies for rare diseases, with an emphasis on innovative treatments. Currently, it does not generate any revenue from its operations as it is in the clinical development phase.
Soleno Therapeutics is navigating a transformative phase with its DCCR tablets for Prader-Willi syndrome, underscoring its commitment to tackling serious genetic disorders. The FDA’s recent extension of the review period for their new drug application until March 2025 underlines the complexity and potential of their product pipeline. Financially, despite a significant increase in net loss to $76.62 million in the third quarter of 2024, compared to $10.86 million last year, Soleno’s strategic R&D investments are in line with expected revenue growth forecasts of 66.5% per year, which is better than the US market average of 8.9%. Furthermore, earnings are expected to grow 67.27% annually as they move toward profitability within three years, reflecting an aggressive growth trajectory fueled by innovative healthcare solutions and robust clinical results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Tenable Holdings, Inc. provides cyber exposure solutions in the Americas, Europe, the Middle East, Africa, Asia Pacific and Japan with a market capitalization of approximately $5.13 billion.
Operations: The company generates revenue primarily from its Security Software & Services segment, totaling approximately $877.60 million.
Tenable Holdings has demonstrated resilience and adaptability in the cybersecurity landscape, most notably expanding its offerings to include new data security posture management (DSPM) and artificial intelligence security posture management (AI-SPM) capabilities. These innovations are critical as they address emerging threats in increasingly complex cloud environments, a strategic move reflected by an annual revenue growth forecast of 9.3%, surpassing the US market average of 8.9%. Additionally, Tenable’s commitment to reinvesting in its technology is evident in its R&D expenditures, keeping the company at the forefront of cybersecurity solutions. This approach not only mitigates risk, but also positions Tenable for future profitability, with profits expected to grow 65.3% per year over the next three years.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on the development and commercialization of therapies for cystic fibrosis, with a market capitalization of approximately $118.90 billion.
Operations: The company’s main revenue stream comes from the pharmaceutical segment, which generates approximately $10.63 billion. As a biotechnology company, it specializes in therapies for cystic fibrosis.
In a challenging landscape, Vertex Pharmaceuticals is steering towards profitability with expected earnings growth of 47.4% per year. This journey is supported by strategic R&D investments, which are crucial for supporting innovation and competitiveness in the biotech sector. Last quarter, Vertex repurchased shares worth $307.58 million, underscoring its confidence in long-term value creation despite current unprofitability. The company also raised its full-year revenue guidance to between $10.8 billion and $10.9 billion, reflecting optimism driven by new product launches and market expansions. These moves highlight Vertex’s robust strategy to leverage scientific advances and increase shareholder value in a rapidly evolving industry landscape.
-
Click through to explore the rest of the 247 US High Growth Tech and AI Stocks now.
-
Do you want to own shares in these companies? Set up your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio’s performance.
-
Simply Wall St is your key to unlocking global market trends, a free easy-to-use app for forward-thinking investors.
This article from Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended as financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. We aim to provide you with targeted, long-term analysis based on fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or quality material. Simply Wall St has no positions in the stocks mentioned.
Companies discussed in this article include NasdaqCM:SLNO NasdaqGS:TENB and NasdaqGS:VRTX.
Do you have feedback on this article? Worried about the content? Please contact us directly. You can also send an email to redactieteam@simplywallst.com
